Skip to Main Content

Speaking Monday night to investors on a conference call, CytoDyn CEO Nader Pourhassan said the company had requested a “conditional” emergency use authorization from the Food and Drug Administration for an experimental Covid-19 antibody treatment, despite its failure in a late-stage clinical trial.

But a “conditional” EUA — as described by CytoDyn’s CEO — does not exist.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • I see you censored my first comment. Afraid of the truth, Adam? Afraid that people will finally see that you’re a paid shill for a known short seller of CytoDyn, Joeseph Seigel of Buyerstrike.

    Another “article” full of lies and distortions. Direct from the FDA’s website: “FDA may establish conditions on an EUA necessary or appropriate to protect the public health.” (Link below) That sentence destroys the entire premise of your story and anyone reading it should not believe anything else that you write. You’re not even trying to be objective and it’s completely obvious here.

    Purposefully writing lies and distortions about CytoDyn is worsening the world’s COVID misery and you should be ashamed. You are an evil human being.

    https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities#conditions

Comments are closed.